Christopher Butler, DO
Pulmonary Disease · Cincinnati, OHNPI 1023215803
Payments from drug & device makers
Across 254 payments — averaging $61.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$12K
- GSK$886
- Inogen, Inc.$496
- Regeneron Healthcare Solutions, Inc.$332
- Takeda Pharmaceuticals U.S.A., Inc.$300
- Grifols USA, LLC$220
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$11,10071%
- Food & beverage$4,45929%
- Education$841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $12,236 |
| GSK | 86 | $886 |
| Inogen, Inc. | 37 | $496 |
| Regeneron Healthcare Solutions, Inc. | 20 | $332 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $300 |
| Grifols USA, LLC | 10 | $220 |
| Sanofi | 9 | $200 |
| Pulmonx Corporation | 4 | $120 |
| Genentech USA, Inc. | 6 | $113 |
| Philips North America LLC | 6 | $106 |
| Boehringer Ingelheim | 5 | $100 |
| Amgen | 4 | $83 |
| Actelion Pharmaceuticals US, Inc. | 4 | $63 |
| United Therapeutics Corporation | 4 | $62 |
| Resmed Corp | 3 | $54 |
| CSL Behring | 2 | $40 |
| Inspire Medical Systems, Inc. | 2 | $37 |
| Insmed, Inc. | 2 | $34 |
| Johnson & Johnson | 1 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| UCB, Inc. | 1 | $24 |
| Phadia US Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,643 in reported general payments places this provider in the 80th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 326 | $289,921 |
| Breo ElliptaFluticasone/Vilanterol | 128 | $72,058 |
| TezspireTezepelumab-Ekko | 13 | $60,956 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 79 | $58,836 |
| SymbicortBudesonide/Formoterol Fumarate | 119 | $42,303 |
| Spiriva RespimatTiotropium Bromide | 32 | $32,904 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 37 | $22,387 |
| Spiriva HandihalerTiotropium Bromide | 15 | $17,829 |
| Incruse ElliptaUmeclidinium Bromide | 30 | $17,295 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 497 | $16,092 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $15,994 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $14,029 |
| DuleraMometasone/Formoterol | 28 | $9,821 |
| Atrovent HfaIpratropium Bromide | 12 | $6,033 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $4,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $886 | $395,268505 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $12,236 | $162,094211 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $100 | $55,29169 claims |
| MerckDulera | $16 | $9,82128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Cincinnati
- Bruce CorserCincinnati$8.2M
- Jean ElwingCincinnati$2.4M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Mohammad SheattCincinnati$405K
- Robert BurkesCincinnati$299K
- Arun JoseCincinnati$287K
- Bruce TrapnellCincinnati$153K
- Rachel FootCincinnati$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.